Metabolomic Study in Huntington's Disease (METABO-HD)

Huntington Disease Clinical Trial

Official title:

Metabolomic Study in Huntington's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03296176
• Other study ID #: 49RC17_0086
• Status: Recruiting
• Phase: N/A
• First received: September 15, 2017
• Last updated: October 30, 2017
• Start date: October 9, 2017
• Est. completion date: September 2019

Study information

• Verified date: September 2017
• Source: University Hospital, Angers
• Contact: Christophe Verny, PU-PH
• Phone: 0241355615
• Email: Chverny[@]chu-angers.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this project is to study Huntington's disease by metabolomic approach.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: September 2019
• Est. primary completion date: September 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

For all groups:

• age between 20 and 70 years

• signature of the informed consent

• covered by social security

For presymptomatic group:

• positive genetic test with CAG repeat length = 37 in HTT gene

• Unified Huntington Disease Rating Scale = 5

For symptomatic group:

• positive genetic test with CAG repeat length = 37 in HTT gene

• The Unified Huntington's Disease Rating Scale motor score = 6

• The Total Functional Capacity score = 11

Exclusion Criteria for all groups:

• participation in another therapeutic trial (3 months exclusion period)

• pregnancy and breastfeeding

• persons deprived of their liberty by judicial or administrative decision

Related Conditions & MeSH terms

• Huntington Disease

Intervention

Biological:
• blood sample
blood sample for metabolome analyse

Locations

Country	Name	City	State
France	CHU Angers	Angers

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	metabolite mass	by chromatography and mass spectrometry	at baseline